In patients with NSCLC, CD8+TRM cells overexpress several T cell inhibitory receptors and exhaustion surface markers and co-express PD-1 and CD39, implying that they are enriched in activated tumor-antigen reactive T cells (74). The gene discussed is ENTPD1; the disease is neoplasm.